Lantheus Holdings, Inc. (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, has appointed Meredith Johnson to Vice President, Pricing & Market Access.
Meredith joins Lantheus Medical Imaging from GE Healthcare where she most recently served as Head of Global Market Access Pharmaceutical Diagnostics. She started her career at GE Healthcare as the Director, Health Economics, Global Evidence Generation. Prior to GE, Meredith held market access leadership roles at Allergan, Sanofi Pasteur MSD, and Covance Market Access Services.
Meredith holds a Bachelor of Arts degree in Anthropology from DePauw University, and earned her MSc in Social Policy and Planning from the London School of Economics and Political Science.
ON Partners consultant Steve Cornacchia is proud to have partnered with Lantheus Medical Imaging and Meredith Johnson on this successful placement. This is the second collaboration between ON Partners and Lantheus, having placed Gerard Hernandez to Vice President, Head of Global DEFINITY Franchise earlier this year. Read more about ON Partners’ recent Life Sciences and Healthcare results, including our placement on the Top 50 Life Sciences and Healthcare industry rankings.
About Lantheus Medical Imaging
Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture, and commercialization of innovative diagnostic and therapeutic agents and products. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Puerto Rico, Canada, and Sweden. For more information, visit www.lantheus.com.
Follow our work, updates, and recent success on Twitter and LinkedIn.
Find our related successful placements of leading executives here.
